ClinicalTrials.gg
CompletedNCT00968591Updated Dec 21, 2020

Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency

A Phase 1 interventional study of Everolimus in Hepatic Insufficiency, sponsored by Novartis Pharmaceuticals. Completed at 3 sites in 3 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-21.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies in Hepatic Insufficiency with a site in Germany — none open to participants now, none under way, none of them phase 3. Hepatic Insufficiency · Germany.

Enrollment
4th of 12
34 · median 30
Started
2009
the only one that year
Phase 1
9 of 14
none open now
Registered
2nd of 14
by date
Lead sponsor
1 of 14
Novartis Pharmaceuticals

Among the 14 studies in Hepatic Insufficiency with a site in Germany, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2009, is one of 9 in phase 1, and was the 2nd registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

None of the 14 studies in Hepatic Insufficiency with a site in Germany is open now. The open studies under Hepatic Insufficiency, anywhere →

Who these studies take

Of the 10 Hepatic Insufficiency studies recruiting now, 3 (30%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Hepatic Insufficiency with a site in Germany as a file.
02

Study summary

This clinical pharmacology research study will assess the safety and pharmacokinetics of the drug everolimus in patients with impaired hepatic function as compared to healthy volunteers.

03

Conditions studied

  • Hepatic Insufficiency

Keywords

  • Hepatic insufficiency
  • liver disease
  • cirrhosis
  • pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects:

  • In good health as determined by past medical history, physical examination, vital signs, , and laboratory test values (except for values related to hepatic insufficiency).

Hepatic impaired subjects:

  • A Classification score clinically determined as Class A, Class B, or Class C.
  • (ANC) > 1000 cells/mm3
  • > 9 mg/mL
  • count > 50,000/mm3 at screening and baseline
  • Serum creatinine ≤ 2.0 x
  • Free of significant medical disorders unrelated to the subject's hepatic disorder

Exclusion criteria

Exclusion Criteria:

All subjects:

  • Significant illness, including infections, or hospitalization within 4 weeks prior to dosing (hospitalization is allowed for hepatic impaired subjects if related to liver disease). Invasive systemic fungal infections need to be fully resolved prior to study entry.
  • History of acute or chronic bronchospastic disease (including asthma and , treated or not treated).
  • History of drug allergy; history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known to the study drug (everolimus) or drugs similar to the study drug (other mTOR inhibitors, e.g., rapamycin or temsirolimus).
  • Active bleeding during the last 28 days prior to dosing, including variceal bleeding.
  • Except for hepatic impairment, any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize the subject in case of participation in the study.
  • Use of tobacco within 7 days prior to dosing or during the study.
  • Consumption of alcohol within 3 days prior to dosing or during the study.
  • Consumption of grapefruits, grapefruit juice, Sevilla oranges, starfruit or related foods within 7 days prior to dosing or during the study period.
  • Use of any drugs known to affect or PgP, including both inhibitors and inducers, within 7 days prior to dosing or during the study.

Hepatic impaired subjects:

  • Symptoms or history of Grade 3 or 4 hepatic encephalopathy within 4 weeks of study entry.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    RAD001

    Drug: Everolimus

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluate the pharmacokinetics of a single oral dose of everolimus in subjects with severely impaired hepatic function (Child-Pugh C) relative to healthy controls. Measure: AUC, Cmax, tmax, λz, Vd/F, CL/F and t1/2

    Time frame: First 8 days

Secondary outcomes

  1. Evaluate the pharmacokinetics of a single oral dose of everolimus in subjects with mild and moderate impaired hepatic function (Child-Pugh A and B, respectively) relative to healthy controls.

    Time frame: First 8 days

  2. Assess the safety and tolerability of a single oral dose of everolimus in subjects with impaired hepatic function (Child-Pugh A, B, and C).

    Time frame: First 8 days plus day 15 and day 28 post-dose follow-ups for safety

  3. Explore correlation between pharmacokinetics and hepatic function parameters

    Time frame: First 8 days

07

Study locations

3 sites
  • Novartis Investigative Site
    Frankfurt, Germany
  • Novartis Investigative Site
    Moscow, Russian Federation
  • Novartis Investigative Site
    Singapore, Singapore
08

References and documents

Publications

  • Peveling-Oberhag J, Zeuzem S, Yong WP, Kunz T, Paquet T, Bouillaud E, Urva S, Anak O, Sellami D, Kobalava Z. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study. Clin Ther. 2013 Mar;35(3):215-25. doi: 10.1016/j.clinthera.2013.02.007. Epub 2013 Mar 1. PubMed 23453404 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009 and a primary completion of Nov 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2009
First posted
Aug 31, 2009
Start
Nov 2009
Primary completionActual
Nov 2010
Last update
Dec 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00968591
Responsible party
Sponsor
First posted
Aug 31, 2009
Start date
Nov 2009
Primary completion
Nov 2010
Last update
Dec 21, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion